Archer Materials Ltd. is a materials technology company, which engages in the developing advanced semiconductor devices and processor chips related to quantum computing and medical diagnostics in Australia. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-08-14. The firm principal activities include technology research and development of the carbon nano onion quantum material (12CQ Project), tunnelling magnetoresistance (TMR) sensor project and graphene-based lab-on-a-chip biosensing chip (biochip) and utilizing semiconductor technology development infrastructure and facilities, research, and development to support technology research and development. The firm is focused on developing its biochip technology, including identifying and developing testing for blood potassium levels, for its first target of hypo- and hyperkalemia detection in chronic kidney disease (CKD) patients. Its biochip marks an inflection point in diagnostics, enabling fast, accurate, and low-cost digital testing.